BIOMAT Database Logo BIOMAT Database Logo

Effects of inhaled nitric oxide on right ventricular function in severe acute respiratory distress syndrome. 1995

R Rossaint, and K Slama, and W Steudel, and H Gerlach, and D Pappert, and S Veit, and K Falke
Klinik für Anaesthesiologie und Operative Intensivemedizin, Universitätsklinikum Rudolf Virchow, Freie Universität Berlin, Germany.

OBJECTIVE To compare the effects of inhaled nitric oxide (NO) and an infusion of prostacyclin (PGI2) on right ventricular function in patients with severe acute respiratory distress syndrome (ARDS). METHODS Randomized prospective short-term study. METHODS Post-surgical ICU in an university hospital. METHODS 10 patients with severe ARDS referred to our hospital for intensive care. METHODS In random sequence the patients inhaled NO at a concentration of 18 parts per million (ppm) followed by 36 ppm, and received an intravenous infusion of PGI2 (4 ng.kg-1.min-1). RESULTS Inhalation of 18 ppm NO reduced the mean (+/- SE) pulmonary artery pressure (PAP) from 33 +/- 2 to 28 +/- 1 mmHg (p = 0.008), increased right ventricular ejection fraction (RVEF), as assessed by thermodilution technique, from 28 +/- 2 to 32 +/- 2% (p = 0.005), decreased right ventricular end-diastolic volume index from 114 +/- 6 to 103 +/- 8 ml.m-2 (p = 0.005) and right ventricular end-systolic volume index from 82 +/- 4 to 70 +/- 5 ml.m-2 (p = 0.009). Mean arterial pressure (MAP) and cardiac index (CI) did not change significantly. The effects of 36 ppm NO were not different from the effects of 18 ppm NO. Infusion of PGI2 reduced PAP from 34 +/- 2 to 30 +/- 2 mmHg (p = 0.02), increased RVEF from 29 +/- 2 to 32 +/- 2% (p = 0.02). Right ventricular end-diastolic and end-systolic volume indices did not change significantly. MAP decreased from 80 +/- 4 to 70 +/- 5 mmHg (p = 0.03), and CI increased from 4.0 +/- 0.5 to 4.5 +/- 0.5 l.min-1.m-2 (p = 0.02). CONCLUSIONS Using a new approach to selective pulmonary vasodilation by inhalation of NO, we demonstrate in this group of ARDS patients that an increase in RVEF is not necessarily associated with a rise in CI. The increase in CI during PGI2 infusion is probably related to the systemic effect of this substance.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007362 Intensive Care Units Hospital units providing continuous surveillance and care to acutely ill patients. ICU Intensive Care Units,Intensive Care Unit,Unit, Intensive Care
D008297 Male Males
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D012128 Respiratory Distress Syndrome A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA. ARDS, Human,Acute Respiratory Distress Syndrome,Adult Respiratory Distress Syndrome,Pediatric Respiratory Distress Syndrome,Respiratory Distress Syndrome, Acute,Respiratory Distress Syndrome, Adult,Respiratory Distress Syndrome, Pediatric,Shock Lung,Distress Syndrome, Respiratory,Distress Syndromes, Respiratory,Human ARDS,Lung, Shock,Respiratory Distress Syndromes,Syndrome, Respiratory Distress
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic

Related Publications

R Rossaint, and K Slama, and W Steudel, and H Gerlach, and D Pappert, and S Veit, and K Falke
Effect of inhaled nitric oxide on right ventricular function in adult respiratory distress syndrome.
May 1995, American journal of respiratory and critical care medicine,
R Rossaint, and K Slama, and W Steudel, and H Gerlach, and D Pappert, and S Veit, and K Falke
Acute respiratory distress syndrome. Inhaled nitric oxide.
December 1998, Respiratory care clinics of North America,
R Rossaint, and K Slama, and W Steudel, and H Gerlach, and D Pappert, and S Veit, and K Falke
Inhaled nitric oxide in acute respiratory distress syndrome.
December 1997, The Journal of trauma,
R Rossaint, and K Slama, and W Steudel, and H Gerlach, and D Pappert, and S Veit, and K Falke
Acute effects of inhaled nitric oxide in adult respiratory distress syndrome.
November 1998, The European respiratory journal,
R Rossaint, and K Slama, and W Steudel, and H Gerlach, and D Pappert, and S Veit, and K Falke
Effects of rescue inhaled nitric oxide on right ventricle and pulmonary circulation in severe COVID-related acute respiratory distress syndrome.
December 2022, Journal of critical care,
R Rossaint, and K Slama, and W Steudel, and H Gerlach, and D Pappert, and S Veit, and K Falke
Inhaled nitric oxide for acute respiratory distress syndrome.
April 2007, BMJ (Clinical research ed.),
R Rossaint, and K Slama, and W Steudel, and H Gerlach, and D Pappert, and S Veit, and K Falke
Role of Inhaled Nitric Oxide in the Management of Severe Acute Respiratory Distress Syndrome.
January 2016, Frontiers in pediatrics,
R Rossaint, and K Slama, and W Steudel, and H Gerlach, and D Pappert, and S Veit, and K Falke
Inhaled nitric oxide and vasoconstrictors in acute respiratory distress syndrome.
August 1999, American journal of respiratory and critical care medicine,
R Rossaint, and K Slama, and W Steudel, and H Gerlach, and D Pappert, and S Veit, and K Falke
Nitric oxide has little effect on acute pulmonary hypertension and right ventricular function during acute respiratory distress syndrome.
May 1997, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
R Rossaint, and K Slama, and W Steudel, and H Gerlach, and D Pappert, and S Veit, and K Falke
Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome.
June 1995, Anesthesiology,
Copied contents to your clipboard!